{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464214831
| IUPAC_name = 4,4'-[propane-2,2-diylbis(thio)]bis(2,6-di-''tert''-butylphenol)
| image = probucol.png
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|probucol}}
| MedlinePlus = a611037
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7277
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 23288-49-5
| ATC_prefix = C10
| ATC_suffix = AX02
| PubChem = 4912
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01599
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4743
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P3CTH044XJ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00476
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 8427
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 608
<!--Chemical data-->
| C=31 | H=48 | O=2 | S=2
| molecular_weight = 516.844 g/mol
| smiles = S(c1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C(Sc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FYPMFJGVHOHGLL-UHFFFAOYSA-N
| synonyms = <small>2,6-di-''tert''-butyl-4-({2-[(3,5-di-''tert''-butyl-4-hydroxyphenyl)sulfanyl]propan-2-yl}sulfanyl)phenol</small>
}}

'''Probucol''' is an anti-hyperlipidemic [[drug]]<ref name="pmid19075491">{{cite journal |author=Yamamoto A |title=A Uniqe Antilipidemic Drug - Probucol |journal=J. Atheroscler. Thromb. |volume= 15|issue= 6|pages= 304–5|date=December 2008 |pmid=19075491 |doi=10.5551/jat.E621 |url=http://www.jstage.jst.go.jp/article/jat/15/6/15_E621/_article }}</ref> initially developed in the treatment of [[coronary artery disease]].

However, clinical trials were stopped after it was found that it may lower HDL in patients with a previous history of heart disease.

Probucol was initially developed in the 1970s by a chemical company to maximize airplane tire longevity.
Probucol is associated with QT interval prolongation.

==Mechanism==
Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption.<ref>[http://www.drugs.com/MMX/Probucol.html "Probucol. Drugs.com web site]</ref>  Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs; this slows the formation of foam cells, which contribute to atherosclerotic plaques.

It is believed to act at [[ABCA1]].<ref name="pmid15514211">{{cite journal |vauthors=Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH |title=Probucol inhibits ABCA1-mediated cellular lipid efflux |journal=Arterioscler. Thromb. Vasc. Biol. |volume=24 |issue=12 |pages=2345–50 |date=December 2004 |pmid=15514211 |doi=10.1161/01.ATV.0000148706.15947.8a |url=http://atvb.ahajournals.org/cgi/pmidlookup?view=long&pmid=15514211}}</ref>

It also lowers levels of [[High-density lipoprotein|HDL]].<ref>{{cite journal | doi = 10.1016/j.atherosclerosis.2007.12.031 | pmid = 18279878 | volume=200 | issue=2 | title=Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling |date=October 2008 | journal=Atherosclerosis | pages=329–35  |vauthors=Miida T, Seino U, Miyazaki O, etal }}</ref>

==References==
{{reflist}}

{{Lipid modifying agents}}

[[Category:Antioxidants]]
[[Category:Phenols]]
[[Category:Thioethers]]
[[Category:Tert-butyl compounds]]


{{cardiovascular-drug-stub}}